Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers

2016 ◽  
Vol 11 (1) ◽  
pp. 105-114 ◽  
Author(s):  
Haruki Kimura ◽  
Kazuyoshi Ohkawa ◽  
Masanori Miyazaki ◽  
Mitsuru Sakakibara ◽  
Kazuho Imanaka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Tumor Markers ◽  
Intermediate Stage ◽  
Barcelona Clinic Liver Cancer ◽  
Cancer Stage ◽  
Serum Tumor Markers

scholarly journals Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience

2021 ◽  
pp. HEP38
Author(s):  
Gerardo Tovar-Felice ◽  
Andrés García-Gámez ◽  
Virgilio Benito-Santamaría ◽  
David Balaguer-Paniagua ◽  
Jordi Villalba-Auñón ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Tumor Response ◽  
Intermediate Stage ◽  
Complete Response ◽  
Barcelona Clinic Liver Cancer ◽  
Cancer Stage ◽  
Single Center Experience ◽  
Unresectable Hepatocellular Carcinoma ◽  
Small Cohort

Background: Transarterial chemoembolization (TACE) is indicated for unresectable hepatocellular carcinoma. Methods: This was a retrospective study of 50 hepatocellular carcinoma patients treated with TACE using doxorubicin-loaded LifePearl™ to investigate the safety and efficacy of TACE. Results: There was no 30-day mortality, and limited adverse events were reported. At best tumor response, complete response and disease control were 58% and 94%, respectively, with a median of 4.5 months of follow-up. Median overall survival was 33.8 months. Patients with Barcelona Clinic Liver Cancer stage 0 and stage A at best tumor response showed a higher complete response rate (83%) than patients with Barcelona Clinic Liver Cancer stage B (complete response: 50%; p = 0.0414). Conclusion: Doxorubicin-loaded LifePearl™ TACE might be an effective treatment, with a good safety profile, for patients with early/intermediate-stage hepatocellular carcinoma. Further prospective data, especially with a small cohort of selected patients, are required to confirm these results.

Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C

2013 ◽  
Vol 45 (6) ◽  
pp. 510-515 ◽  
Author(s):  
Jing-Houng Wang ◽  
Yuan-Hung Kuo ◽  
Chih-Chi Wang ◽  
Chao-Long Chen ◽  
Yu-Fen Cheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Surgical Resection ◽  
Barcelona Clinic Liver Cancer ◽  
Cancer Stage

scholarly journals Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B

Gut and Liver ◽  
2020 ◽  
Vol 14 (3) ◽  
pp. 377-386 ◽  
Author(s):  
Jeong-Ju Yoo ◽  
Su Jong Yu ◽  
Bora Lee ◽  
Eun Ju Cho ◽  
Jeong-Hoon Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Barcelona Clinic Liver Cancer ◽  
Cancer Stage ◽  
Ambulatory Patients
Sign in / Sign up

Export Citation Format

Share Document